Lepu Medical Technology researches and develops interventional cardiology devices, with a portfolio spanning structural heart and cardiac rhythm management.
Lepu Medical secures NMPA approval for its Continuous Renal Replacement Therapy (CRRT) dialyzer. The registration marks a key milestone for the company’s kidney-care product line, expanding its offerings in critical care medical devices.
Prof. Yang Chen presents real-world data on the **ScienCrown TAVR system** at **CSI Asia-Pacific 2026** in Bangkok. The session highlights clinical insights from **Fuwai Hospital**, part of China’s National Center for Cardiovascular Diseases. The presentation focuses on the system’s performance in transcatheter aortic valve replacement procedures, drawing from ongoing research and patient outcomes.
LEPU Medical adds two new interventional products to its portfolio, both certified by China’s National Medical Products Administration (NMPA). The certifications mark the latest step in the company’s innovation pipeline, though specific product details remain undisclosed.
LEPU MEDICAL secures NMPA approval for its GenTadpole® Coronary Balloon Dilatation Catheter. The device is designed for coronary interventions, expanding treatment options in cardiovascular procedures. This regulatory milestone enables broader market access for LEPU MEDICAL’s medical technology portfolio.